A possible usage of a CDK4 inhibitor for breast cancer stem cell-targeted therapy

Biochemical and Biophysical Research Communications

Volumn 430, Issue 4, 2013, Pages 1329-1333

  Han, Yu Kyeong ^a   Lee, Jae Ho ^a   Park, Ga Young ^a   Chun, Sung Hak ^a   Han, Jeong Yun ^a   Kim, Sung Dae ^a   Lee, Janet ^c   Lee, Chang Woo ^c,d   Yang, Kwangmo ^a,b   Lee, Chang Geun ^a  

^a Dongnam Institute of Radiological and Medical Science   (South Korea)

^b Korea Institute of Radiation and Medical Science   (South Korea)

^c Sungkyunkwan University School of Medicine   (South Korea)

^d Sungkyunkwan University   (South Korea)

Author keywords

Breast cancer; Cancer stem cells; CDK4; Differentiation therapy; Radiotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 4 INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STEM CELL; CELL CYCLE ARREST; CELL DEATH; CELL DIFFERENTIATION; CELL POPULATION; CELL PROLIFERATION; CELL STRAIN MCF 7; CONTROLLED STUDY; IRRADIATION; PHENOTYPE; PRIORITY JOURNAL;

APOPTOSIS; BREAST NEOPLASMS; CELL CYCLE CHECKPOINTS; CYCLIN-DEPENDENT KINASE 4; FEMALE; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASTIC STEM CELLS; PROTEIN KINASE INHIBITORS; RADIATION TOLERANCE; RADIATION-SENSITIZING AGENTS;

EID: 84872862548     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.10.119     Document Type: Article

References (33)

1. Lapidot T., Sirard C., Vormoor J., Murdoch B., Hoang T., Caceres-Cortes J., Minden M., Paterson B., Caligiuri M.A., Dick J.E. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994, 367:645-648.
2. Bonnet D., Dick J.E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med. 1997, 3:730-737.
3. Ricci-Vitiani L., Lombardi D.G., Pilozzi E., Biffoni M., Todaro M., Peschle C., De Maria R. Identification and expansion of human colon-cancer-initiating cells. Nature 2007, 445:111-115.
4. O'Brien C.A., Pollett A., Gallinger S., Dick J.E. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007, 445:106-110.
5. Collins A.T., Berry P.A., Hyde C., Stower M.J., Maitland N.J. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res. 2005, 65:10946-10951.
6. Hurt E.M., Kawasaki B.T., Klarmann G.J., Thomas S.B., Farrar W.L. CD44+ CD24(-) prostate cells are early cancer progenitor/stem cells that provide a model for patients with poor prognosis. Br. J. Cancer 2008, 98:756-765.
7. Singh S.K., Clarke I.D., Terasaki M., Bonn V.E., Hawkins C., Squire J., Dirks P.B. Identification of a cancer stem cell in human brain tumors. Cancer Res. 2003, 63:5821-5828.
8. Al-Hajj M., Wicha M.S., Benito-Hernandez A., Morrison S.J., Clarke M.F. Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. USA 2003, 100:3983-3988.
9. O'Brien C.A., Kreso A., Dick J.E. Cancer stem cells in solid tumors: an overview. Semin. Radiat. Oncol. 2009, 19:71-77.
10. Zhou B.B., Zhang H., Damelin M., Geles K.G., Grindley J.C., Dirks P.B. Tumour-initiating cells: challenges and opportunities for anticancer drug discovery. Nat. Rev. Drug Discov. 2009, 8:806-823.
11. Winquist R.J., Furey B.F., Boucher D.M. Cancer stem cells as the relevant biomass for drug discovery. Curr. Opin. Pharmacol. 2010, 10:385-390.
12. Diehn M., Cho R.W., Lobo N.A., Kalisky T., Dorie M.J., Kulp A.N., Qian D., Lam J.S., Ailles L.E., Wong M., Joshua B., Kaplan M.J., Wapnir I., Dirbas F.M., Somlo G., Garberoglio C., Paz B., Shen J., Lau S.K., Quake S.R., Brown J.M., Weissman I.L., Clarke M.F. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 2009, 458:780-783.
13. Frank N.Y., Schatton T., Frank M.H. The therapeutic promise of the cancer stem cell concept. J. Clin. Invest. 2010, 120:41-50.
14. Park C.Y., Tseng D., Weissman I.L. Cancer stem cell-directed therapies: recent data from the laboratory and clinic. Mol. Ther. 2009, 17:219-230.
15. Gupta P.B., Onder T.T., Jiang G., Tao K., Kuperwasser C., Weinberg R.A., Lander E.S. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 2009, 138:645-659.
16. Dean M., Fojo T., Bates S. Tumour stem cells and drug resistance. Nat. Rev. Cancer 2005, 5:275-284.
17. Jordan C.T., Guzman M.L. Mechanisms controlling pathogenesis and survival of leukemic stem cells. Oncogene 2004, 23:7178-7187.
18. Ponti D., Zaffaroni N., Capelli C., Daidone M.G. Breast cancer stem cells: an overview. Eur. J. Cancer 2006, 42:1219-1224.
19. Shipitsin M., Campbell L.L., Argani P., Weremowicz S., Bloushtain-Qimron N., Yao J., Nikolskaya T., Serebryiskaya T., Beroukhim R., Hu M., Halushka M.K., Sukumar S., Parker L.M., Anderson K.S., Harris L.N., Garber J.E., Richardson A.L., Schnitt S.J., Nikolsky Y., Gelman R.S., Polyak K. Molecular definition of breast tumor heterogeneity. Cancer Cell 2007, 11:259-273.
20. - breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis. Breast Cancer Res. 2006, 8:R59.
21. Abraham B.K., Fritz P., McClellan M., Hauptvogel P., Athelogou M., Brauch H. Prevalence of CD44+/CD24-/low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis. Clin. Cancer Res. 2005, 11:1154-1159.
22. Hwang-Verslues W.W., Chang P.H., Wei P.C., Yang C.Y., Huang C.K., Kuo W.H., Shew J.Y., Chang K.J., Lee E.Y., Lee W.H. MiR-495 is upregulated by E12/E47 in breast cancer stem cells, and promotes oncogenesis and hypoxia resistance via downregulation of E-cadherin and REDD1. Oncogene 2011, 30:2463-2474.
23. Mittnacht S. Control of pRB phosphorylation. Curr. Opin. Genet. Dev. 1998, 8:21-27.
24. Malumbres M., Barbacid M. To cycle or not to cycle: a critical decision in cancer. Nat. Rev. Cancer 2001, 1:222-231.
25. Knudsen E.S., Knudsen K.E. Tailoring to RB: tumour suppressor status and therapeutic response. Nat. Rev. Cancer 2008, 8:714-724.
26. Keyomarsi K., Pardee A.B. Redundant cyclin overexpression and gene amplification in breast cancer cells. Proc. Natl. Acad. Sci. USA 1993, 90:1112-1116.
27. Gillett C., Fantl V., Smith R., Fisher C., Bartek J., Dickson C., Barnes D., Peters G. Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. Cancer Res. 1994, 54:1812-1817.
28. Ormandy C.J., Musgrove E.A., Hui R., Daly R.J., Sutherland R.L. Cyclin D1, EMS1 and 11q13 amplification in breast cancer. Breast Cancer Res. Treat. 2003, 78:323-335.
29. Ginestier C., Hur M.H., Charafe-Jauffret E., Monville F., Dutcher J., Brown M., Jacquemier J., Viens P., Kleer C.G., Liu S., Schott A., Hayes D., Birnbaum D., Wicha M.S., Dontu G. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007, 1:555-567.
30. Croker A.K., Allan A.L. Inhibition of aldehyde dehydrogenase (ALDH) activity reduces chemotherapy and radiation resistance of stem-like ALDHhiCD44(+) human breast cancer cells. Breast Cancer Res. Treat. 2012, 133:75-87.
31. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
32. McDermott S.P., Wicha M.S. Targeting breast cancer stem cells. Mol. Oncol. 2010, 4:404-419.
33. Yin H., Glass J. The phenotypic radiation resistance of CD44+/CD24(-or low) breast cancer cells is mediated through the enhanced activation of ATM signaling. PLoS One 2011, 6:e24080.